Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst S.r.l. Irccs
Clinical trials sponsored by Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst S.r.l. Irccs, explained in plain language.
-
Promising combo aims to delay hormone therapy in prostate cancer
Disease control Recruiting nowThis study tests whether adding a targeted radiation drug (Lu-PSMA) to standard stereotactic radiotherapy can better control prostate cancer that has spread to 1-3 small spots. About 70 men with asymptomatic metastases will be randomly assigned to receive either the combination o…
Phase: PHASE2 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated May 17, 2026 00:53 UTC
-
New trial aims to find best treatment for returning leukemia
Disease control Recruiting nowThis study tests whether a gentler, low intensity therapy works better than strong chemotherapy for people whose acute myeloid leukemia (AML) has come back or not responded to treatment. About 339 adults with AML in their first or second relapse will be randomly assigned to one o…
Phase: PHASE3 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
4,000 leukemia patients tracked to see what treatments work best in real life
Knowledge-focused Recruiting nowThis study will follow 4,000 adults whose acute myeloid leukemia has come back or not responded to treatment. Researchers will collect information on which treatments patients receive and how long they live, without giving any new medicine themselves. The goal is to learn what re…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated May 15, 2026 11:58 UTC